Get the Stockscreener App
1.34
2.29%
0.03
After Hours:
1.35
0.01
+0.75%
Editas Medicine Inc stock is traded at $1.34, with a volume of 2.45M.
It is up +2.29% in the last 24 hours and down -32.32% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
See More
Previous Close:
$1.31
Open:
$1.32
24h Volume:
2.45M
Relative Volume:
0.98
Market Cap:
$110.61M
Revenue:
$78.12M
Net Income/Loss:
$-153.22M
P/E Ratio:
-0.6537
EPS:
-2.05
Net Cash Flow:
$-136.90M
1W Performance:
+10.74%
1M Performance:
-32.32%
6M Performance:
-71.24%
1Y Performance:
-85.85%
1-Day Range:
$1.26
$1.35
1-Week Range:
$1.17
$1.415
52-Week Range:
$1.1601
$11.58
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
1.34 | 110.61M | 78.12M | -153.22M | -136.90M | -2.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-13-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-13-24 | Downgrade | Stifel | Buy → Hold |
| Dec-13-24 | Downgrade | Truist | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Underperform |
| Nov-06-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-08-24 | Upgrade | BofA Securities | Neutral → Buy |
| May-09-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-24-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-18-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-29-23 | Upgrade | Stifel | Hold → Buy |
| Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-13-22 | Initiated | Citigroup | Neutral |
| Dec-06-22 | Resumed | Credit Suisse | Neutral |
| Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-22 | Initiated | BofA Securities | Neutral |
| Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-09-21 | Upgrade | Truist | Hold → Buy |
| Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-16-21 | Initiated | Goldman | Sell |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-26-21 | Downgrade | Truist | Buy → Hold |
| Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-03-20 | Initiated | Robert W. Baird | Underperform |
| Jun-18-20 | Resumed | SunTrust | Buy |
| Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-10-18 | Initiated | Guggenheim | Neutral |
| Sep-21-18 | Initiated | Raymond James | Outperform |
| May-15-18 | Reiterated | Chardan Capital Markets | Buy |
| Feb-13-18 | Initiated | CLSA | Underperform |
| Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Hold |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
| Jun-02-16 | Initiated | Jefferies | Hold |
| Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-29-16 | Initiated | JP Morgan | Neutral |
| Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
Short Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Increases By 5.4% - MarketBeat
Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
State Street Corp Cuts Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $7.00 Average PT from Brokerages - MarketBeat
Editas Medicine (STU:8EM) Cyclically Adjusted FCF per Share : €-1.69 (As of Sep. 2024) - GuruFocus.com
Editas Medicine stock plunges to 52-week low of $1.27 - Investing.com
Cambridge company is laying of 180 people, 65% of its workforce - MSN
Editas Medicine's SWOT analysis: gene editing firm pivots strategy amid stock uncertainty - Investing.com
Editas to cut 65% of workforce in strategy shift; shelves lead gene-editing program - MSN
JP Morgan Downgrades Editas Medicine (EDIT) - MSN
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce - MSN
EDIT Stock Falls On Decision To End Reni-Cel Studies, Cut Workforce - Barchart
Editas Medicine (NASDAQ:EDIT) Price Target Lowered to $5.00 at Evercore ISI - MarketBeat
JPMorgan Chase & Co. Downgrades Editas Medicine (NASDAQ:EDIT) to Underweight - MarketBeat
Five things: Editas cuts, CVS shares, Moderna's name and the best birthday gift ever - The Business Journals
Brokerages downgrade gene editing company Editas to 'hold', shares slump 23% - MSN
Editas cut to equal weight by Wells Fargo over reni-cel positioning - MSN
Chardan Capital Downgrades Editas Medicine (EDIT) - MSN
Barclays Cuts Editas Medicine (NASDAQ:EDIT) Price Target to $3.00 - MarketBeat
Editas Medicine price target lowered to $8 from $10 at Baird - Yahoo Finance
Editas Medicine to reduce about 65% of its workforce over the next six months - ETHRWorld.com
Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts - GuruFocus.com
Truist cuts Editas Medicine stock to Hold, removes price target By Investing.com - Investing.com Canada
Editas Medicine (NASDAQ:EDIT) Price Target Lowered to $4.00 at Royal Bank of Canada - MarketBeat
Editas Medicine (EDIT) PT Lowered to $5 at Evercore ISI - StreetInsider.com
Cambridge biotech company lays off more than half its employees - NBC Boston
Gene-editing pioneer Editas lays off more than half its employees - The Business Journals
Editas to cut 65% of workforce in strategy shift; shelves lead gene-editing program (NASDAQ:EDIT) - Seeking Alpha
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Editas Medicine's (EDIT) "Neutral" Rating Reaffirmed at Chardan Capital - MarketBeat
Editas Medicine (NASDAQ:EDIT) Price Target Cut to $8.00 by Analysts at Robert W. Baird - MarketBeat
Editas to lay off staff after search for sickle cell partner comes up empty - Yahoo Finance
Editas Medicine (NASDAQ:EDIT) Downgraded to Hold Rating by Truist Financial - MarketBeat
Chardan Capital Markets Downgrades Editas Medicine (EDIT) to Neutral - StreetInsider.com
Editas Medicine (NASDAQ:EDIT) Cut to "Hold" at Stifel Nicolaus - MarketBeat
Editas Axes 60% of Staff, Sickle Cell Therapy After Failing to Find Partner - BioSpace
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 - Benzinga
Editas axes two-thirds of its staff, including its CMO - pharmaphorum
Editas Medicine stock plunges to 52-week low at $1.89 By Investing.com - Investing.com Canada
Editas stock downgraded to hold, price target slashed - Investing.com
Editas Medicine's SWOT analysis: gene editing firm's stock faces pivotal phase - Investing.com Nigeria
Editas Medicine, Inc. Announces Management Changes - Marketscreener.com
Editas shifts focus to in vivo CRISPR gene editing - Investing.com India
Editas to reduce about 65% of its workforce over the next six months - 1470 & 100.3 WMBD
Editas Medicine Announces Strategic Transition to in vivo - GlobeNewswire
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years - The Manila Times
Editas Medicine Pivots Gene Editing Strategy, Cutting 65% of Workforce - MarketWatch
Editas Medicine (EDIT) Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years - StreetInsider.com
Editas Medicine stock plunges to 52-week low at $1.89 - Investing.com India
Genome Editing Market is encountering new opportunities & - openPR
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
2.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):